BioSpace News Archive

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today announced the successful completion of an End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for the DTX301 ornithine transcarbamylase (OTC) deficiency gene therapy program.

Vaxess Technologies, Inc., a biotechnology company developing vaccines and therapeutics delivered through a next-generation sustained-release intradermal microneedle patch, announced it was awarded a Commercialization Readiness Program (CRP) grant from the National Institute of Allergy and Infectious Diseases (NIAID grant number SB1AI164584), a part of the U.S. National Institutes of Health (NIH).

Soundbite announces FDA 510(k) Approval for SoundBite® Crossing System - Peripheral (SCS-P) with the 0.014” Active Wire (14P).

Delpor, Inc. (Delpor), a clinical stage biopharmaceutical company that utilizes innovative technologies in order to develop once-yearly therapies for chronic conditions, today announced that it has initiated and dosed the first patient in a phase 1b/2a clinical trial of DLP-114, a long-acting formulation of the antipsychotic risperidone for schizophrenia maintenance therapy.

Cerner Corporation, a global healthcare technology company, announced that it has been named #57 among America’s top employers for diversity by Forbes, up 230 rankings from last year.

Global health service company Cigna Corporation announced that Brian Evanko, executive vice president and chief financial officer, will present at the 2021 BofA Securities Health Care Conference on May 13, 2021 through a virtual webcast.

Because of the aberration in results which began in March 2020 due to the impact of restrictions on “nonessential” medical procedures, Utah Medical Products, Inc. will report 2021 quarterly income statement results compared to the same periods in both 2020 and 2019.

Ceapro Inc.(TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced operational highlights and financial results for the fourth quarter and full year ended December 31, 2020.

The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) today announced five new investments aimed at speeding the development of new and improved immunotherapies for the treatment of blood cancers.

A group of leading public and private cancer-focused organizations today announced a Multi-Cancer Early Detection (MCED) consortium to evaluate new technologies that have the potential to reduce cancer mortality by enabling earlier detection of cancer before it has spread, when treatment is potentially curative.